ulcerative colitis

Literature Sharing | J AM CHEM SOC | Probiotic-Drug Conjugates Achieve Site-Specific Probiotic Colonization and On-Demand Drug Release to Combat Ulcerative Colitis and Its Complications

by
Literature Sharing | J AM CHEM SOC | Probiotic-Drug Conjugates Achieve Site-Specific Probiotic Colonization and On-Demand Drug Release to Combat Ulcerative Colitis and Its Complications

1. Research Background Ulcerative colitis (UC) is a chronic intestinal disease that severely affects the quality of life of patients and significantly increases the risk of colorectal cancer (CAC) associated with colitis, posing a major threat to patient survival. Current treatment strategies for UC are limited by single therapeutic mechanisms, uncontrolled drug release, and non-specific … Read more

Oral Probiotic-Drug Conjugates for Targeted Colonization and On-Demand Drug Release in the Treatment of Ulcerative Colitis and Its Complications

by
Oral Probiotic-Drug Conjugates for Targeted Colonization and On-Demand Drug Release in the Treatment of Ulcerative Colitis and Its Complications

Special Statement: Due to limited knowledge, there may be omissions and errors. Readers are encouraged to read critically and provide constructive feedback. Oral Probiotic-Drug Conjugates for Targeted Colonization and On-Demand Drug Release in the Treatment of Ulcerative Colitis and Its Complications Introduction This article constructs an orally administered, ROS-responsive probiotic-drug conjugate that achieves targeted colonization … Read more

Probiotic–Drug Conjugates Achieve Synchronized Site-Specific Probiotic Colonization and On-Demand Drug Release against Ulcerative Colitis and Its Complications

by
Probiotic–Drug Conjugates Achieve Synchronized Site-Specific Probiotic Colonization and On-Demand Drug Release against Ulcerative Colitis and Its Complications

Hello everyone, today I would like to share an article published in JACS titled “Probiotic–Drug Conjugates Achieve Synchronized Site-Specific Probiotic Colonization and On-Demand Drug Release against Ulcerative Colitis and Its Complications.” The corresponding authors are Professors Gao Huiyuan, Sun Jin, and Sun Mengchi from Shenyang Pharmaceutical University, who study active substances from traditional Chinese medicine, … Read more

JACS | New Direction for ADC: Triggerable Probiotic-Drug Conjugates

by
JACS | New Direction for ADC: Triggerable Probiotic-Drug Conjugates

Ulcerative colitis (UC) is a chronic, recurrent inflammatory bowel disease that not only significantly reduces the quality of life for patients but also sharply increases the risk of colorectal cancer (CAC) due to prolonged inflammation. Currently, oral probiotics are considered a promising biological therapy for UC due to their advantages in regulating gut microbiota and … Read more